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Abstract 
 
Migraine is a neurovascular disorder that involves activation of the trigeminovascular system and 
cranial vasodilation mediated by release of calcitonin gene-related peptide (CGRP). 
The gold standard for acute migraine treatment are the triptans, 5-HT1B/1D/(1F) receptor agonists. 
Their actions are thought to be mediated through activation of: (i) 5-HT1B receptors in cranial blood 
vessels with subsequent cranial vasoconstriction; (ii) prejunctional 5-HT1D receptors on trigeminal 
fibres that inhibit trigeminal CGRP release; and (iii) 5-HT1B/1D/1F receptors in central nervous system 
involved in (anti)nociceptive modulation. Unfortunately, coronary arteries also express 5-HT1B 
receptors whose activation would produce coronary vasoconstriction; hence, triptans are 
contraindicated in patients with cardiovascular disease. In addition, since migraineurs have an 
increased cardiovascular risk, it is important to develop antimigraine drugs devoid of vascular (side) 
effects. 
Ditans, here defined as selective 5-HT1F receptor agonists, were developed on the basis that 
most of the triptans activate trigeminal 5-HT1F receptors, which may explain part of the triptans’ 
antimigraine action. Amongst the ditans, lasmiditan: (i) fails to constrict human coronary arteries; and 
(ii) is effective for the acute treatment of migraine in preliminary Phase III clinical trials. Admittedly, 
the exact site of action is still unknown, but lasmiditan possess a high lipophilicity, which suggests a 
direct action on the central descending antinociceptive pathways. Furthermore, since 5-HT1F receptors 
are located on trigeminal fibres, they could modulate CGRP release.  
This review will be particularly focussed on the similarities and differences between the 
triptans and the ditans, their proposed sites of action, side effects and their cardiovascular risk profile. 
 
Keywords: triptans; ditans; serotonin; migraine; cardiovascular safety  
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Abbreviations: 
 
5-HT 5-hydroxytryptamine 
BBB blood brain barrier  
CGRP  calcitonin gene-related peptide  
DHSC dorsal horn of the spinal cord 
logDpH7.4 distribution coefficient at physiological pH 
MMA middle meningeal artery 
ND not defined 
NTS nucleus tractus solitarius 
PAG periaqueductal grey area 
pEC50 negative logarithm of the half maximal effective concentration  
PVN hypothalamic pararaventricular nucleus 
TG trigeminal ganglion 
TNC trigeminal nucleus caudalis 
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1. Introduction  
Migraine is a debilitating neurovascular disorder characterized by recurring unilateral pulsating 
headaches of moderate to severe intensity, associated with nausea, photophobia and/or phonophobia, 
lasting from 4 to 72 hours (Headache Classification Committee of the International Headache Society, 
2013). In the Global Burden of Disease Study, migraine was ranked as the third disabler in women, 
sixth disabler when taking both genders into account, and the most disabling of all neurological 
disorders, affecting approximately 15% of the world population (Steiner, Stovner, & Birbeck, 2013), 
with a profound negative effect on the patient’s quality of life (Ruiz de Velasco, González, Etxeberria, 
& Garcia-Monco, 2003). Furthermore, this neurovascular disorder represents an economic loss of €20 
billion in Europe every year (Gustavsson et al., 2011). Thus, migraine is a public health problem that 
affects both the individual and society 
1.1 Pathophysiology of migraine 
Throughout the years, several theories regarding the pathophysiology of migraine have emerged 
(Goadsby et al., 2017). In the late 1930’s and early 1940’s, Wolff’s group described migraine as a 
disorder of vascular origin, with an intense extracranial vasodilation as the cause of migraine pain 
(Graham & Wolff, 1938; Ray & Wolff, 1940). Decades later, Moskowitz introduced the neurogenic 
theory, where trigeminovascular axons from blood vessels of the dura mater released vasoactive 
peptides producing an sterile inflammatory response followed by pain (Moskowitz, Romero, Reinhard, 
Melamed, & Pettibone, 1979). Nowadays, migraine is considered as a neurovascular disorder that 
involves activation of the trigeminovascular system (Edvinsson, 2017; Edvinsson & Uddman, 2005), 
presumably followed by vasodilation mainly mediated by the release of calcitonin gene-related peptide 
(CGRP), a neuropeptide present in perivascular sensory fibres (Goadsby, Lipton, & Ferrari, 2002; 
Villalón & Olesen, 2009).   
1.2 Treatment of migraine 
Despite the long history of migraine treatment, effective antimigraine drugs have been, until very 
recently, limited in number (for references see Villalón, Centurión, Valdivia, de Vries, & Saxena, 
2003). Basically, pharmacological treatment of migraine can be divided into prophylactic drugs, 
designed to reduce the frequency and severity of migraine attacks, and acutely acting drugs, aimed to 
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reverse the attack once it has begun, including the associated symptoms. The majority of migraine 
patients only need acute treatment, nevertheless, migraineurs that suffer from frequent attacks or have 
contraindications for the use of acutely acting drugs, are also prescribed prophylactic drugs (Dib, 
2008). The prophylactic treatment will not be discussed here as it is falls beyond the scope of the 
present review. 
The acute treatment can be further subdivided in specific (ergot derivatives, triptans, gepants, 
“ditans”), and non-specific (nonsteroidal anti-inflammatory drugs, analgesics) antimigraine drugs 
(Dib, 2008; Marmura, Silberstein, & Schwedt, 2015). While non-specific drugs aim to treat migraine 
as a general headache or other pain, specific treatment is developed based on the neurovascular basis 
of migraine. Thus, these drugs target the modulation of the trigeminovascular system, the CGRP-
mediated vasodilation (i.e. extracranial vasoconstriction, inhibition of CGRP release, CGRP receptor 
antagonism) and/or the pain perception pathway, amongst others. On this basis, CGRP receptor 
antagonists (gepants) are a likely candidate for the acute treatment of migraine, and indeed, they were 
effective in clinical trials (Doods et al., 2000; Edvinsson & Linde, 2010; Villalón & Olesen, 2009); 
however, due to pharmacokinetic and/or hepatotoxic limitations none of the gepants have yet reached 
the market (Negro, Lionetto, Simmaco, & Martelletti, 2012). Currently, a potential concern with 
gepants includes the cardiovascular side effects when used chronically, considering the physiological 
protective role of CGRP in maintaining cardiovascular homeostasis in ischemic events (for further 
references see MaassenVanDenBrink, Meijer, Villalón, & Ferrari, 2016).  Several drugs targeting the 
CGRP receptor are presently under development for the acute and prophylactic treatment of migraine 
(Schuster & Rapoport, 2017; Tso & Goadsby, 2017). 
During the last 40 years, the target for selective antimigraine drugs has been the serotoninergic 
signalling. Long before the discovery of CGRP and its fundamental role in migraine, increased urinary 
and plasma levels of serotonin (5-hydroxytryptamine, 5-HT) and its metabolites  were described 
(Sicuteri, Testi, & Anselmi, 1961; Somerville, 1976). Further studies showed that an intravenous 
infusion of 5-HT was capable of aborting migraine attacks (Kimball, Friedman, & Vallejo, 1960) and 
that efficacious antimigraine drugs like methysergide and ergotamine were acting on, amongst other 
receptors, 5-HT1 receptors (Apperley, Feniuk, Humphrey, & Levy, 1980; Humphrey et al., 1988). In 
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this review, the main focus will be on the triptans, 5-HT1B/1D/(1F) receptor agonists, that are currently 
considered the gold standard for acute migraine treatment, and on the novel “ditans” (in this review 
defined as selective 5-HT1F receptor agonists), not only developed based on the neurovascular origin 
of migraine, but also in view of the cardiovascular risk profile of migraine patients (Chang, Donaghy, 
& Poulter, 1999; Etminan, Takkouche, Isorna, & Samii, 2005; Linstra, Ibrahimi, Terwindt, Wermer, & 
MaassenVanDenBrink, 2017; Sacco, Ornello, Ripa, Pistoia, & Carolei, 2013; Scher et al., 2005; 
Schurks et al., 2009; Spector et al., 2010; Tzourio et al., 1995; Vanmolkot, Van Bortel, & de Hoon, 
2007) . 
2. Triptans 
As mentioned in the above section, the role of serotoninergic neurotransmission in migraine  led to the 
design of antimigraine drugs that targeted the 5-HT receptors (Kimball et al., 1960; Sicuteri et al., 
1961; Somerville, 1976); however, the exact 5-HT receptors involved in the relief of migraine attacks 
were unknown. Indeed, intravenous infusion of 5-HT was able to abort migraine attacks, but 
considering that there are fourteen 5-HT receptors (Villalón & MaassenVanDenBrink, 2017), and they 
were all activated, numerous side effects were observed (Kimball et al., 1960). After several studies 
using selective agonists and antagonists, it was demonstrated that the therapeutic action of 5-HT was 
mediated by “5-HT1-like receptors” that constricted cranial blood vessels (Apperley et al., 1980; 
Feniuk & Humphrey, 1992; Humphrey et al., 1988), and the first triptan was developed: sumatriptan 
(Humphrey, 2007). In the early 1990s, sumatriptan was officially introduced to the market (The 
Subcutaneous Sumatriptan International Study Group 1991). In view of the low oral bioavailability 
and lipophilicity of sumatriptan (Fowler et al., 1991), as well as the vast market potential, “second 
generation” triptans (zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, frovatriptan, 
donitriptan and avitriptan) were developed, with a chemical structure similar to sumatriptan (see Fig. 
1), but in general with higher oral availability and lipophilicity (see Table 1), as well as a longer 
plasma half-life (de Vries, Villalón, & Saxena, 1999; Tfelt-Hansen, De Vries, & Saxena, 2000; 
Villalón & MaassenVanDenBrink, 2017).  
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2.1 Mechanism of action 
Initially, it was described that the therapeutic action of 5-HT on migraine was mediated by activation 
of “5-HT1-like” receptors (Feniuk & Humphrey, 1992). Years later, based on structural, transductional 
and operational criteria, these receptors were classified into 5-HT1B and 5-HT1D receptors (for further 
references see Hoyer et al., 1994; Saxena, de Vries, & Villalón, 1998). 
Triptans are 5-HT1B/1D receptor agonists, and a grand majority of them are also 5-HT1F 
receptor agonists (see Table 2, Fig. 2). Sumatriptan, as previously mentioned, has low lipophilicity 
(see Table 1) and cannot cross the blood brain barrier (BBB). For a drug to be considered able to cross 
the BBB, it should have a distribution coefficient at physiological pH (logDpH7.4) higher than -1 
(Brodie, Kurz, & Schanker, 1960; Levin, 1980).  Notably, second generation triptans were developed 
with higher lipophilicity (Fowler et al., 1991) but their ability to cross the BBB is in controversy, since 
their reported logDpH7.4 values are not consistent amongst studies (see Table 1). Furthermore, it is 
important to consider the possible interactions between triptans and BBB efflux transporters (e.g. P-
glycoprotein) that limit the central actions of triptans, as it has been reported for eletriptan (Evans et 
al., 2003).  
2.2 Cardiovascular (side) effects 
The initially proposed therapeutic action of triptans is through the selective vasoconstriction of cranial 
blood vessels due to the high expression of 5-HT1B receptors in this vasculature (Feniuk & Humphrey, 
1992; Longmore et al., 1997) in comparison with peripheral blood vessels (MaassenVanDenBrink et 
al., 2000). In agreement with this, in vitro studies have shown that at therapeutic concentrations 
triptans contract the middle meningeal artery (MMA) (MaassenVanDenBrink et al., 2000). 
Furthermore, magnetic resonance angiography studies demonstrated that migraine attacks are 
associated with dilation of the extra- and intracerebral arteries, ipsilateral to the headache side; and 
that contraction of dural (but not intracranial) arteries by triptans, is associated with headache relief 
(Asghar et al., 2011), although it is worth mentioning that further results of the same group have been 
inconsistent (Amin et al., 2013; Benemei et al., 2017; MaassenVanDenBrink, Ibrahimi, & Edvinsson, 
2013) and it is still a matter of debate to what extent the vascular action of the triptans contributes to 
their therapeutic efficacy.  
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Unfortunately, studies have consistently shown that triptans induce an increase in blood 
pressure (Hoon, Willigers, Troost, Struijker‐Boudier, & Bortel, 2000) and contraction of coronary 
arteries (MaassenVanDenBrink, Reekers, Bax, Ferrari, & Saxena, 1998a; MaassenVanDenBrink et al., 
2000; MacIntyre, Bhargava, Hogg, Gemmill, & Hillis, 1993; Nilsson et al., 1999), which is more 
pronounced in the distal than in the proximal portion of the human coronary artery (Chan et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Chemical structures of the triptans, alniditan and the selective 5-HT1F receptor agonists. It is 
worth remarking the presence of the indole group (in blue) in all the structures, with exception of 
lasmiditan and alniditan (Villalón & MaassenVanDenBrink, 2017). 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
6 
 
 
 
 
 
 
Table 1. Reported LogDpH7.4 values for triptans. Compounds with values higher than -1 are considered 
to be able to cross the BBB.  
 Sumatriptan Zolmitriptan Naratriptan Rizatriptan Almotriptan Eletriptan Frovatriptan 
Fox (2000) -1.5 -1 -0.2 -0.7 ND ND -1 
Ferrari, Goadsby, 
Roon, and Lipton 
(2002) 
-1.3 -0.7 -0.2 -0.7 +0.35 +0.5 ND 
Glennon and 
Dukat (2002) 
-1.7 -0.8 -1.2 -1.4 -0.5 +0.2 -2.1 
Milton et al. (2002) ND ND ND ND ND +1.1 ND 
Pascual and 
Muñoz (2005) 
-1.3 -0.7 -0.2 -0.7 -2.1 +0.5 ND 
Cheng et al. (2012) -1.4 -1.5 ND -0.8 +0.4 +0.2 -1.9 
ND. Not defined 
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Table 2. Summary of pEC50 values of cAMP (5-HT1 and 5-HT7) and IP (5-HT2) assays of individual 
antimigraine drugs at 5-HT receptors (Rubio-Beltrán et al., 2017). These values represent the negative 
logarithm of the molar concentration of these compounds at which 50% of their maximal response is 
exerted. 
 
5-HT1A 5-HT1B 5-HT1D* 5-ht1E 5-HT1F 5-HT2A 5-HT2B 5-HT7 
Ergotamine tartrate 9.78 9.94 9.43 5.95 5.97 9.25 8.72 7.09 
Sumatriptan succinate <5 7.32 8.30 5.99 8.03 <5 <5 5.22 
Zolmitriptan <5 7.87 9.51 8.18 8.00 <5 <5 6.28 
Naratriptan hydrochloride <5 8.05 8.80 7.75 8.38 <5 <5 <5 
Rizatriptan benzoate <5 7.08 8.11 7.34 6.54 <5 5.49 <5 
Almotriptan malate 4.00 7.08 7.75 5.00 7.79 <5 5.20 5.00 
Eletriptan hydrobromide <5 8.00 9.04 7.53 8.13 6.07 6.81 6.45 
Frovatriptan racemate <5 7.98 8.36 5.04 7.10 <5 <5 7.42 
Donitriptan hydrochloride 5.94 9.96 9.51 4.77 <5 8.10 7.61 5.23 
Avitriptan fumarate <5 8.57 9.27 5.52 7.09 6.91 6.41 5.38 
Alniditan dihydrochloride 7.00 8.87 8.20 5.68 5.92 <5 7.15 6.32 
Lasmiditan hemisuccinate <5 <5 6.64 6.17 8.43 <5 <5 <5 
LY334370 hydrochloride 5.84 6.52 6.92 7.53 9.08 <5 <5 <5 
LY344864 hydrochloride <5 <5 6.93 6.22 8.72 <5 <5 <5 
* pEC50 values correspond to [
35
S]GTPγS assay 
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Fig. 2. Summary of agonist profiles of triptans, ditans (here considered as selective 5-HT1F receptor 
agonists) and other 5-HT receptor ligands, for 5-HT1B, 5-HT1D and 5-HT1F receptors (pEC50>7). *In 
view of the high affinity of alniditan for the 5-HT1B/1D receptors (pEC50 cAMP 8.87 and 8.20, 
respectively), we classified it as a triptan, despite its generic name (Rubio-Beltrán et al., 2017). 
 
Currently, although there is still a debate on whether the therapeutic action of triptans relays 
on their vasoconstrictive properties, it is clear that coronary vasoconstriction is a drug class effect of 
the triptans as 5-HT1B receptor agonists (MaassenVanDenBrink & Saxena, 2004). Therefore, triptans 
are contraindicated in migraine patients with cardiovascular disease (Dodick et al., 2004). 
Additionally, it is important to consider that migraineurs are known to have an increased risk of 
haemorrhagic (Sacco et al., 2013) and ischemic (Chang et al., 1999; Etminan et al., 2005; Schurks et 
al., 2009; Spector et al., 2010; Tzourio et al., 1995) stroke, with women presenting a higher risk 
(Linstra et al., 2017). Also, an altered arterial function (Vanmolkot et al., 2007), and a higher risk of 
myocardial infarction and coronary heart disease (Scher et al., 2005) have been described. 
Nonetheless, the use of triptans does not seem to increase the risk of stroke, myocardial infarction, 
cardiovascular death, ischemic heart disease or mortality (Chan, Vermeersch, de Hoon, Villalón, & 
MaassenVanDenBrink, 2011; Hall, Brown, Mo, & MacRae, 2004; Wammes-van der Heijden, 
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Rahimtoola, Leufkens, Tijssen, & Egberts, 2006). However, taken together, their coronary 
vasoconstrictor potential justifies the contraindication of the triptans in patients with cardiovascular 
risk factors. 
2.3 Neuronal effects 
Although sumatriptan does not cross the BBB (Ferrari et al., 2002), it has long been speculated that 
during a migraine attack there would be a disruption of the BBB, which would enable the triptans, 
even those with a low lipophilicity, to exert a central effect. However, it has recently been 
demonstrated that there is no disruption of the BBB during a migraine attack (Amin et al., 2017; 
Hougaard et al., 2017), thus excluding a central action for the triptans, except for those with a high 
lipophilicity. Besides the potential role for blood vessels in the pathophysiology of migraines, this 
suggests that actions of the triptans can well be mediated through neuronal structures that are not 
protected by the BBB, as it is the case for the pituitary gland, choroid plexus and, most importantly, 
the trigeminal ganglion (TG) (Eftekhari et al., 2015), a key structure in migraine pathophysiology. 
Indeed, treatment with sumatriptan reduces CGRP plasma levels as migraine lessens (Goadsby & 
Edvinsson, 1993). More recently, sumatriptan was also shown to inhibit capsaicin-induced trigeminal 
CGRP release in healthy volunteers (Ibrahimi, Danser, Terwindt, van den Meiracker, & 
MaassenVanDenBrink, 2016). Furthermore, expression of prejunctional 5-HT1D receptors has been 
described in trigeminovascular nociceptive neurons (Classey, Bartsch, & Goadsby, 2010; Hou et al., 
2001; Longmore et al., 1997) which could suggest a role in the modulation of CGRP release, as well 
as plasma protein extravasation (Buzzi & Moskowitz, 1990). Remarkably, based on the prejunctional 
location of 5-HT1D receptors in the TG, PNU-142633, a selective 5-HT1D receptor agonist, was 
developed for the acute treatment of migraine, and showed a superior potency over sumatriptan for 
blocking plasma protein extravasation. Unfortunately, it was not effective in the acute treatment of 
migraine (Gómez-Mancilla et al., 2001). It is worth mentioning that PNU-142633 was developed 
based on the gorilla 5-HT1D receptor, which could explain its lack of efficacy, and thus a role for the 
5-HT1D receptor in the treatment of migraine cannot categorically be ruled out. Besides, it has been 
shown that activation of 5-HT1B, but not 5-HT1D receptors inhibits CGRP release in the pithed rat 
model (González-Hernández et al., 2010), indicating that, while 5-HT1D receptor activation may 
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contribute to the therapeutic actions of triptans, it may not be their main site of action. Further studies 
are needed to completely elucidate the role of 5-HT1D receptor activation in migraine treatment.  
 As discussed earlier, second generation triptans were developed with higher lipophilicity than 
sumatriptan (de Vries et al., 1999; Tfelt-Hansen et al., 2000). Therefore, some of them may be able to 
cross the BBB (Ferrari et al., 2002; Muñoz-Islas et al., 2006). Although the lipophilicity of triptans 
correlates with central side effects, it does not seem to be related to their efficacy (Pascual & Muñoz, 
2005), and there is no consistency in the lipophilicity reported in literature (see Table 2). Nevertheless, 
we cannot categorically exclude additional therapeutic actions mediated via activation of 5-HT1B/1D/(1F) 
receptors in the central nervous system by highly lipophilic triptans (Deleu & Hanssens, 2000). In 
accordance with this, it has been shown that vasodilation of the canine external carotid artery induced 
by intracarotid administration of capsaicin, is inhibited by spinal (but not intravenous) administration 
of sumatriptan via activation of 5-HT1B receptors; in contrast, intravenous administration of the highly 
lipophilic donitriptan inhibits the capsaicin-induced vasodilation, also mediated by activation of 
5-HT1B receptors (Muñoz-Islas et al., 2006; Muñoz-Islas et al., 2009).  
Several studies have described 5-HT1B and (presynaptic) 5-HT1D receptors in the dorsal horn 
of the spinal cord (DHSC) (Castro et al., 1997), substantia nigra, globus pallidus (Castro et al., 1997; 
Lindhe et al., 2011), nucleus tractus solitarius (NTS), trigeminal nucleus caudalis (TNC) (Castro et al., 
1997; Longmore et al., 1997), periaqueductal grey area (PAG) (Bartsch, Knight, & Goadsby, 2004; 
Castro et al., 1997), the ventroposteromedial nucleus of the thalamus (Shields & Goadsby, 2006), 
hypothalamic paraventricular nucleus (PVN) (Robert et al., 2013) and the rostral ventromedial 
medulla (Vera-Portocarrero, Ossipov, King, & Porreca, 2008), structures previously associated with 
nociceptive and anti-nociceptive pathways (Baumeister et al., 1988; Condés-Lara et al., 2006; Fields, 
Basbaum, Clanton, & Anderson, 1977; Foreman, Beall, Coulter, & Willis, 1976; Gerhart, Yezierski, 
Fang, & Willis, 1983; Lewis, Baldrighi, & Akil, 1987; Loher, Burgunder, Weber, Sommerhalder, & 
Krauss, 2002; Olszewski, 1950; Reynolds, 1969). Furthermore, it has been shown that spinal 5-
HT1B/1D/1F receptors are involved in the serotonergic descending inhibitory pain system (Ávila-Rojas et 
al., 2015; Granados-Soto et al., 2010; Kayser, Aubel, Hamon, & Bourgoin, 2002; Kayser, 
Latremoliere, Hamon, & Bourgoin, 2011; Vidal-Cantú et al., 2016). Of special interest, intravenous 
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administration of naratriptan (Cumberbatch, Hill, & Hargreaves, 1998; Goadsby & Knight, 1997) 
results in inhibition of the spinal TNC. Also, the PAG, more specifically the ventrolateral division, is 
activated by afferents from the TG  (Hoskin, Bulmer, Lasalandra, Jonkman, & Goadsby, 2001; Keay 
& Bandler, 1998; Knight & Goadsby, 2001), and microinjection of naratriptan in this structure inhibits 
nociceptive dural responses (Bartsch et al., 2004). Moreover, the PVN, that has been previously shown 
to participate in the endogenous modulation of pain (Condés-Lara et al., 2006; DeLaTorre et al., 2009) 
sends projections to the PAG (Condés-Lara et al., 2015) and the spinal trigeminal nucleus (Robert et 
al., 2013), and microinjection of naratriptan in this structure, attenuates dural-evoked 
trigeminovascular responses (Robert et al., 2013). Thus, indeed highly lipophilic triptans could not 
only act through the vasoconstriction of extracranial vasculature and inhibition of the release of 
CGRP, but also through the activation of the descending inhibitory pain system and/or the inhibition 
of nociceptive transmission (see Fig. 3). Interestingly, most of these studies were performed using 
naratriptan, a highly lipophilic triptan that has a high affinity for the 5-HT1F receptor (see Table 2). 
Furthermore, although antagonists were used to confirm the role of 5-HT1B/1D receptors, there is no 
selective antagonist commercially available for the 5-HT1F receptor yet. Therefore, the involvement of 
this receptor in the neuronal actions of triptans can neither be confirmed nor excluded and requires 
further studies.  
3. Ditans and the 5-HT1F receptor 
Triptan monotherapy is ineffective for approximately 25% of migraineurs and in 40% of acute 
migraine attacks (Diener & Limmroth, 2001). Several studies have tried to elucidate the lack of 
efficacy in some migraineurs, but were unable to explain why some patients are responders to the 
triptans while others are nonresponders. Whereas a difference in efficacy could be due to 
pharmacokinetic factors for some of the oral triptans, pharmacokinetics did not seem to be responsible 
for differences in efficacy in response to subcutaneous sumatriptan (Visser et al., 1996), nor  
polymorphisms in the 5-HT1B and 5-HT1F receptor genes were able to explain differences in clinical 
responses to sumatriptan (MaassenVanDenBrink et al., 1998b; MaassenVanDenBrink et al., 1998c; 
Mehrotra et al., 2007). Moreover, as previously discussed, migraine patients are known to have an 
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increased cardiovascular risk; therefore, it is important to develop novel effective antimigraine drugs 
that are devoid of cardiovascular side effects.  
Several triptans bind to the 5-HT1F receptor (see Table 2). Also, as will be discussed later, 
5-HT1F receptors are expressed in several structures associated with migraine pathophysiology and 
with the (neuronal) therapeutic actions of triptans. This led to the development of selective 5-HT1F 
receptor agonists as possible option for migraine treatment. Several selective 5-HT1F receptor agonists 
have been developed (see Fig. 1), including LY344864, an aminocarbazole, LY334370, a 4-(3-
indolyl)piperidine (Glennon & Dukat, 2002) and lasmiditan (COL-144, LY573144), a piridinoyl-
piperidine (Nelson et al., 2010). While the selective 5-HT1F receptor agonists were referred to as 
SSOFRAs (Selective Serotonin One F Receptor Agonists) for some time, in the last years the term 
“ditan” has been accepted as a synonymous of selective 5-HT1F receptor agonist (Hoffmann & 
Goadsby, 2014). In this context, it is important to consider alniditan, a 5-HT1A/1B/1D receptor agonist 
with only low 5-HT1F receptor affinity (see Table 2), suggesting that the suffix “ditan” is merely to 
distinguish novel acutely acting (5-HT1 receptor agonists) antimigraine drugs from triptans, without 
any structural (see Fig. 2) and/or pharmacological criteria (see Table 2). As the following paragraph is 
only focused on 5-HT1F receptor agonists, alniditan will not be further discussed when ditans are 
mentioned. 
3.1 Location 
The human 5-HT1F receptor was first identified and cloned in 1993 (Adham et al., 1993). It has been 
described in the TG (Bouchelet, Cohen, Case, Séguéla, & Hamel, 1996; Classey et al., 2010; 
Kovalchin, Ghiglieri, Zanelli, Ings, & Mathers, 2016), globus pallidus, NTS, substantia nigra, PAG, 
DHSC (Castro et al., 1997), caudate nucleus (Waeber & Moskowitz, 1995), caudate putamen, nucleus 
accumbens (Lucaites, Krushinski, Schaus, Audia, & Nelson, 2005), and the TNC (Amrutkar et al., 
2012; Bruinvels et al., 1994; Castro et al., 1997; Waeber & Moskowitz, 1995). Interestingly, it has 
also been shown to be expressed on cerebrovascular tissues (Bouchelet et al., 1996) as well as 
peripheral arteries (Nilsson et al., 1999).  
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3.2 Preclinical studies 
Selective 5-HT1F receptor agonists were developed as a novel therapeutic option for migraineurs, 
including those with increased cardiovascular risk. Therefore, the main concern was to study the (lack 
of) vascular effects, as well as their efficacy on predictive models of migraine treatment.  
3.2.1 Cardiovascular (side) effects 
An established in vitro model used to analyse potential contraction of human arteries is the contraction 
of the rabbit saphenous vein (Cohen, Johnson, Schenck, & Phebus, 1997). LY334370 (Cohen & 
Schenck, 2000; Johnson et al., 1997), LY344864 (Cohen & Schenck, 1999; Cohen & Schenck, 2000) 
and lasmiditan (Nelson et al., 2010) lacked vasoconstrictor effects in this model. Furthermore, in two 
in vivo studies in dogs, intracarotid administration of LY344864 did not affect carotid blood flow 
(Centurión, Sánchez-López, De Vries, Saxena, & Villalón, 2001), and responses to continuous 
intravenous infusions of lasmiditan, in escalating cumulative doses, failed to constrict the coronary 
and carotid arteries; sumatriptan, on the other hand, constricted both arteries at clinically relevant 
doses (Rubio-Beltrán et al., 2016). Furthermore, in in vitro studies in human mammary and coronary 
arteries, lasmiditan was also devoid of vasoconstrictor properties, while sumatriptan was shown to 
contract already at subtherapeutic concentrations (Rubio-Beltrán et al., 2016; Rubio-Beltrán et al., 
2017). It is worth mentioning that in this study, also a threshold stimulation with the thromboxane A2 
analogue U46619 was performed to potentially “unmask” vasoconstrictor responses in the internal 
mammary artery; notably, sumatriptan contracted at even lower concentrations, while lasmiditan failed 
to produce vasoconstriction. Similarly, pharmacological activation of 5-HT1F receptors failed to 
produce vasoconstriction in human cerebral and MMA (Bouchelet, Case, Olivier, & Hamel, 2000; 
Razzaque et al., 1999). 
3.2.2 Neuronal effects 
A number of studies have shown that intravenous administration of the selective 5-HT1F receptor 
agonists LY334370 (Johnson et al., 1997), LY344864 (Phebus et al., 1997) and lasmiditan (Nelson et 
al., 2010) inhibits protein plasma extravasation in the dura mater. However, it is important to consider 
that the selective 5-HT1D receptor agonist PNU-142633 also showed a high potency for inhibiting 
protein plasma extravasation, but was not effective in the acute treatment of  migraine (Gómez-
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Mancilla et al., 2001). Similar failures in the acute treatment of migraine were observed with 
endothelin receptor antagonists (May et al., 1996) and the highly potent inhibitor of protein plasma 
extravasation CP 122,288 (Roon et al., 2000). Therefore, it seems likely that 5-HT1F receptor agonists 
act through additional pathways, for instance, modulation of the trigeminovascular system, inhibition 
of the CGRP-mediated vasodilation and/or modulation of the pain perception pathway (see Fig. 3). In 
accordance with these potential mechanisms, activation of 5-HT1F receptors has been shown to inhibit 
the activation of second order neurons in the TNC in mice (Mitsikostas, Sánchez Del Río, & Waeber, 
2002), rats (Mitsikostas, Sánchez del Río, Moskowitz, & Waeber, 1999; Nelson et al., 2010; 
Shepheard et al., 1999; Vila-Pueyo et al., 2016) and cats (Goadsby & Classey, 2003), suggesting a 
modulation of the trigeminovascular system. Moreover, an in vitro study with LY344864 showed an 
inhibition of CGRP release in rat dura mater, but not in TNC or TG (Amrutkar et al., 2012). In 
contrast, a recent study showed that lasmiditan inhibits CGRP release in mouse dura mater, TG and 
TNC (Labastida-Ramírez et al., 2017), although only supratherapeutic concentrations were studied. 
Therefore, more in vitro and in vivo studies (e.g. closed cranial window model) are required to confirm 
5-HT1F receptor involvement in the inhibition of CGRP release. Nonetheless, in the pithed rat model it 
has been shown that activation of 5-HT1F receptors inhibits the release of CGRP from perivascular 
nerve fibres (González-Hernández et al., 2011).  
 Furthermore, the expression of 5-HT1F receptors in the globus pallidus, NTS, the DHSC 
(Castro et al., 1997), caudate nucleus (Waeber & Moskowitz, 1995), putamen and the nucleus 
accumbens (Lucaites et al., 2005), structures associated with (anti)nociceptive pathways (Fields et al., 
1977; Foreman et al., 1976; Ikeda, Takasu, & Murase, 2014; Lewis et al., 1987; Lineberry & Vierck, 
1975; Loher et al., 2002), suggests a possible role for 5-HT1F receptor activation in the modulation of 
nociceptive impulses. 
3.3 Clinical studies 
Twenty years have passed since the development of LY334370 (Shepheard et al., 1999); nowadays, 
two more 5-HT1F receptor agonists have been synthesized, namely, LY344864 (Phebus et al., 1997) 
and lasmiditan (Nelson et al., 2010). Only LY334370 and lasmiditan have reached clinical trials. 
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Fig. 3. Structures associated with migraine pathophysiology and/or treatment. The proposed 
therapeutic action of triptans is through the selective vasoconstriction of the MMA (green), as well as 
the inhibition of CGRP release from the sensory fibres and the modulation of the TG, since they are 
not protected by the BBB, where also 5-HT1F receptors have been described (orange). Highly 
lipophilic triptans could also act on the ventroposteromedial nucleus of the thalamus, PVN, PAG, LC, 
NTS, TNC, RVM and the (DH) SC, where 5-HT1B and 5-HT1D receptors have been described and 
whose activation could also modulate the activity of the TG and/or the (anti)nociception pathways 
(purple). Furthermore, 5-HT1F receptors have also been reported in PAG, TG, TNC and the (DH)SC, 
which suggests a role in the modulation of the trigeminal responses as well as possible action on the 
(anti)nociceptive pathways (BOLD letters). BBB: blood brain barrier; CGRP: calcitonin-like related 
peptide; DHSC: dorsal horn of the spinal cord; MMA: middle meningeal artery; NTS: nucleus tractus 
solitarius; PAG: periaqueductal grey area; PVN: paraventricular nucleus of the hypothalamus;  RVM: 
rostral ventromedial medulla; TG: trigeminal ganglion; TNC: trigeminal nucleus caudalis. 
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3.3.1 LY334370 
The prototype for the 5-HT1F receptor agonists reached phase II of clinical trials (Goldstein et al., 
2001), and the results were favourable for the acute treatment of migraine, as sustained headache 
response rates were higher on 60 mg (37%) and 200 mg (52%) compared to placebo (8%; p<0.001). 
However, further trials were halted due to observed liver damage in beagle dogs after treatment for 
longer than one month (Ramadan, Skljarevski, Phebus, & Johnson, 2003). It is worth mentioning that 
liver damage was not reported in other species, discarding hepatotoxicity as a drug class effect. 
3.3.2 Lasmiditan 
Considered as the most promising of the 5-HT1F receptor agonists, lasmiditan differs from LY334370 
and LY344864, as it does not possess the indole group (see Fig. 1).  
Five phase I trials have been completed (Liefaard et al., 2009; Pilgrim et al., 2009; Raffaelli, 
Israel, Neeb, & Reuter, 2017) for intravenous and oral formulations for safety, bioavailability, 
tolerability and pharmacokinetic studies. In 2007, a phase II study for the intravenous formulation was 
conducted (Ferrari et al., 2010), and later on, in 2009 for the oral formulation (Farkkila et al., 2012). In 
both cases, lasmiditan was shown to be safe and effective in the acute treatment of migraine.  
 Phase III trials are ongoing, with preliminary statements showing positive results as the 
percentage of patients pain free at two hours was higher for 100 mg (28%) and 200 mg (32%), 
compared to placebo (15%; p<0.001; "CoLucid Pharmaceuticals Announces Achievement of Both 
Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in 
Migraine," 2016). It is worth mentioning, that the first phase III trial (“SAMURAI”, NCT02439320) 
included a majority of migraineurs (80%) that had cardiovascular conditions or cardiovascular risk 
factors (i.e. obesity, hypertension, hyperlipidemia), the main group of patients that would benefit from 
the lack of vasoconstrictive properties. Two more phase III trials (“SPARTAN”, NCT02605174: 
“GLADIATOR”, NCT02565186) are under way and are aimed to compare different doses of 
lasmiditan, and to evaluate the safety and efficacy of long term use, respectively. Recently, 
preliminary results from SPARTAN have been released and showed that at two hours following the 
first dose of lasmiditan, the percentage of pain-free patients was statistically significantly higher for 
50 mg (28%, p=0.003); 100 mg (31%, p<0.001) and 200 mg (38%, p<0.001) compared to placebo 
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(21%) (Wietecha, Kuca, Case, Selzler, & Aurora, 2017). Only patients that received lasmiditan in 
previous trials are allowed to be included in the GLADIATOR trial. It is worth mentioning that no 
direct comparison has been performed between triptans and lasmiditan in clinical studies. Future phase 
III trials with a triptan as an active comparator would allow a better evaluation of their efficacy. 
4. Conclusions 
Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine 
treatment that have been proven effective.  Unfortunately, they are contraindicated in patients with 
cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVanDenBrink et al., 1998a; 
MaassenVanDenBrink & Saxena, 2004). Furthermore, triptans are not effective in 25% of migraine 
patients (Diener & Limmroth, 2001); thus, it is important to develop new antimigraine drugs that are 
cardiovascularly completely safe and at least equally effective. The vasoconstrictor properties of 
triptans are thought to be mediated via activation of 5-HT1B receptors in blood vessels; this has led, in 
view of the contraindications in patients with cardiovascular pathologies, to the development of 
antimigraine drugs targeting the 5-HT1D and 5-HT1F receptors. While 5-HT1D receptor activation was 
not effective in the acute treatment of migraine (Gómez-Mancilla et al., 2001), the 5-HT1F receptor 
agonists have shown to be effective (Farkkila et al., 2012; Ferrari et al., 2010). Furthermore, predictive 
preclinical models of migraine have shown that lasmiditan does not cause vasoconstriction and that its 
antimigraine effects are likely mediated via neural modulation (Labastida-Ramírez et al., 2017; Nelson 
et al., 2010; Rubio-Beltrán et al., 2016; Vila-Pueyo et al., 2016). Thus, 5-HT1F receptor agonists may 
provide migraine patients with another type of specific acutely acting antimigraine drug, with a 
cardiovascular safety advantage over the triptans, and with a mechanism of action that is likely to be, 
at least partly, different from that of the triptans.  
 Based on the lack of vasoconstrictive properties and its presumably neuronal mode of action, 
5-HT1F receptor agonists can be considered as an entity apart from that of the triptans in antimigraine 
therapy. 
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